Romiplostim Treatment in Adults with Immune Thrombocytopenia of Varying Duration and Severity
Ann Janssens, Paul Woodard, Kerry Dillingham(Amgen (United Kingdom)), Robert Bird(Princess Alexandra Hospital), Georg Kreuzbauer(Amgen (Switzerland)), Peter A.W. te Boekhorst(Erasmus MC), Michael Steurer(Innsbruck Medical University), Tomáš Kozák(The University of Texas System), Maria Gabriella Mazzucconi(Sapienza University of Rome), Michael D. Tarantino(Bleeding & Clotting Disorders Institute), Ralph V. Boccia(Center for Cancer and Blood Disorders), María Fernanda López Fernández(Complexo Hospitalario Universitario A Coruña)
Cited by 28
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2010|587
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A
|New England Journal of Medicine|2016|494